These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 28155013)

  • 21. BCL-2 as a therapeutic target in chronic lymphocytic leukemia.
    Daniel C; Mato AR
    Clin Adv Hematol Oncol; 2017 Mar; 15(3):210-218. PubMed ID: 28398276
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A targeted therapy for protein and lipid kinases in chronic lymphocytic leukemia.
    Robak P; Robak T
    Curr Med Chem; 2012; 19(31):5294-318. PubMed ID: 22830347
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Current Treatment Options in Relapsed and Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: a Review.
    Islam P
    Curr Treat Options Oncol; 2023 Sep; 24(9):1259-1273. PubMed ID: 37407887
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of constitutive and BCR-induced Syk activation downregulates Mcl-1 and induces apoptosis in chronic lymphocytic leukemia B cells.
    Gobessi S; Laurenti L; Longo PG; Carsetti L; Berno V; Sica S; Leone G; Efremov DG
    Leukemia; 2009 Apr; 23(4):686-97. PubMed ID: 19092849
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The dual inhibitor of the phosphoinositol-3 and PIM kinases, IBL-202, is effective against chronic lymphocytic leukaemia cells under conditions that mimic the hypoxic tumour microenvironment.
    Crassini K; Shen Y; O'Dwyer M; O'Neill M; Christopherson R; Mulligan S; Best OG
    Br J Haematol; 2018 Sep; 182(5):654-669. PubMed ID: 29978459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.
    Baudot AD; Jeandel PY; Mouska X; Maurer U; Tartare-Deckert S; Raynaud SD; Cassuto JP; Ticchioni M; Deckert M
    Oncogene; 2009 Sep; 28(37):3261-73. PubMed ID: 19581935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of BCR signaling using the Syk inhibitor TAK-659 prevents stroma-mediated signaling in chronic lymphocytic leukemia cells.
    Purroy N; Carabia J; Abrisqueta P; Egia L; Aguiló M; Carpio C; Palacio C; Crespo M; Bosch F
    Oncotarget; 2017 Jan; 8(1):742-756. PubMed ID: 27888629
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Idelalisib for the treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Barrientos JC
    Future Oncol; 2016 Sep; 12(18):2077-94. PubMed ID: 27324214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia.
    Raghunathan V; Fan G; Kittai AS; Okada C; Danilov AV; Spurgeon SE
    Eur J Haematol; 2021 Feb; 106(2):294-297. PubMed ID: 33089525
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SYK inhibition thwarts the BAFF - B-cell receptor crosstalk and thereby antagonizes Mcl-1 in chronic lymphocytic leukemia.
    Paiva C; Rowland TA; Sreekantham B; Godbersen C; Best SR; Kaur P; Loriaux MM; Spurgeon SEF; Danilova OV; Danilov AV
    Haematologica; 2017 Nov; 102(11):1890-1900. PubMed ID: 28838991
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia.
    Kipps TJ; Eradat H; Grosicki S; Catalano J; Cosolo W; Dyagil IS; Yalamanchili S; Chai A; Sahasranaman S; Punnoose E; Hurst D; Pylypenko H
    Leuk Lymphoma; 2015; 56(10):2826-33. PubMed ID: 25797560
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Venetoclax: Bcl-2 inhibition for the treatment of chronic lymphocytic leukemia.
    Del Poeta G; Postorino M; Pupo L; Del Principe MI; Dal Bo M; Bittolo T; Buccisano F; Mariotti B; Iannella E; Maurillo L; Venditti A; Gattei V; de Fabritiis P; Cantonetti M; Amadori S
    Drugs Today (Barc); 2016 Apr; 52(4):249-60. PubMed ID: 27252989
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The biological rationale and clinical efficacy of inhibition of signaling kinases in chronic lymphocytic leukemia.
    de Weerdt I; Eldering E; van Oers MH; Kater AP
    Leuk Res; 2013 Jul; 37(7):838-47. PubMed ID: 23597579
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paving the way for new agents; is standard chemotherapy part of the treatment paradigm for chronic lymphocytic leukemia in the future?
    Frustaci AM; Montillo M; Picardi P; Mazzucchelli M; Cairoli R; Tedeschi A
    Expert Rev Hematol; 2016 Jul; 9(7):679-93. PubMed ID: 27253240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolving Strategies for the Treatment of Chronic Lymphocytic Leukemia in the Upfront Setting.
    Bachow SH; Lamanna N
    Curr Hematol Malig Rep; 2016 Feb; 11(1):61-70. PubMed ID: 26951237
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evolution of CLL treatment - from chemoimmunotherapy to targeted and individualized therapy.
    Burger JA; O'Brien S
    Nat Rev Clin Oncol; 2018 Aug; 15(8):510-527. PubMed ID: 29777163
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Inhibition of B cell receptor signaling: a first targeted therapeutic approach for chronic lymphocytic leukemia and other B cell lymphomas].
    Mráz M; Doubek M; Mayer J
    Klin Onkol; 2013; 26(3):179-85. PubMed ID: 23763320
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activities of SYK and PLCgamma2 predict apoptotic response of CLL cells to SRC tyrosine kinase inhibitor dasatinib.
    Song Z; Lu P; Furman RR; Leonard JP; Martin P; Tyrell L; Lee FY; Knowles DM; Coleman M; Wang YL
    Clin Cancer Res; 2010 Jan; 16(2):587-99. PubMed ID: 20068106
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy.
    Small S; Ma S
    Curr Hematol Malig Rep; 2021 Aug; 16(4):325-335. PubMed ID: 34021874
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Next Generation of Targeted Molecules for the Treatment of Chronic Lymphocytic Leukemia.
    Jeyakumar D; O'Brien S
    Oncology (Williston Park); 2016 Nov; 30(11):1008-15. PubMed ID: 27854102
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.